Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A polypeptide having Calcineurin-binding activity selected from the group consisting of:

(a) polypeptides comprising the amino acid sequence set forth in SEQ ID No: 1 or SEQ ID No. 2.

(b) polypeptides corresponding to the polypeptides of (a) contained in NF-Atx family proteins;

(c) polypeptides of (a) or (b) in which one or more amino acids are added, deleted, substituted, and/or inserted; and

(d) fusion polypeptides comprising a polypeptide of (a), (b) or (c) and one or more other polypeptides.

2. (Original) A DNA encoding the polypeptide of claim 1.

3. (Original) A vector comprising the DNA of claim 2.

4. (Original) A transformant carrying the DNA of claim 2 or the vector of claim 3.

5. (Previously presented) A method for producing the polypeptide of claim 1, and recovering the expressed polypeptide from the transformant or the culture supernatant.

6. (Currently Amended) A method for screening a compound that inhibits the interaction between Calcineurin and NF-AT, the method comprising:

(a) contacting ~~the~~ a polypeptide ~~of claim 1~~ having Calcineurin-binding activity selected from the group consisting of:

(i) a polypeptide consisting essentially of the amino acid sequence set forth in SEQ ID NO: 2 or 4;

(ii) a polypeptide consisting essentially of a fragment of a NF-ATx family protein, wherein the fragment corresponds to the polypeptide of (i);

(iii) a polypeptide of (i) or (ii) in which 1 to 30 amino acids are added, deleted, substituted, and/or inserted; and

(iv) a fusion polypeptide consisting essentially of the polypeptide of (i), (ii) or (iii) connected to one or more other polypeptides;

with Calcineurin in the presence or absence of a sample;

(b) detecting the binding activity of the polypeptide to Calcineurin; and

(c) selecting a compound that reduces the binding activity compared with the binding activity detected in the absence of the sample.

7.(Original) A compound isolable by the screening method of claim 6.

8. (Original) A pharmaceutical composition comprising the compound of claim 7 as an active ingredient.

9. (Original) A pharmaceutical composition comprising the polypeptide of claim 1 as an active ingredient.

10. (Original) A method of suppressing immune, the method comprising administering the pharmaceutical composition of claim 8 to a patient in need of immunosuppression.

11. (Original) A method of suppressing immune, the method comprising administering the pharmaceutical composition of claim 9 to a patient in need of immunosuppression.

12. (Original) A method of preventing the hypertrophy of cardiac smooth muscle or vascular smooth muscle, the method comprising administering the pharmaceutical composition of claim 8 to a patient.

13. (Original) A method of preventing the hypertrophy of cardiac smooth muscle or vascular smooth muscle, the method comprising administering the pharmaceutical composition of claim 9 to a patient.

14. (Previously presented) A method comprising culturing the transformant of claim 4, and recovering the expressed polypeptide from the transformant or the culture supernatant.

15. (New) The method of claim 6, wherein the polypeptide having Calcineurin-binding activity is selected from the group consisting of:

(i) a polypeptide consisting essentially of the amino acid sequence set forth in SEQ ID No: 2 or 4;

(ii) a polypeptide of (i) in which 1 to 30 amino acids are added, deleted, substituted, and/or inserted; and

(iii) a fusion polypeptide consisting essentially of the polypeptide of (i) or (ii) connected to one or more other polypeptides.

16. (New) The method of claim 6, wherein the polypeptide having Calcineurin-binding activity is selected from the group consisting of:

(i) a polypeptide consisting essentially of the amino acid sequence set forth in SEQ ID No. 2 or 4;

(ii) a polypeptide of (i) in which 1 to 15 amino acids are added, deleted, substituted, and/or inserted; and

(iii) a fusion polypeptide consisting essentially of the polypeptide of (i) or (ii) connected to one or more other polypeptides.

17. (New) The method of claim 6, wherein the polypeptide having Calcineurin-binding activity is selected from the group consisting of:

(i) a polypeptide consisting essentially of the amino acid sequence set forth in SEQ ID No. 2 or 4;

(ii) a polypeptide of (i) in which 1 to 10 amino acids are added, deleted, substituted, and/or inserted; and

(iii) a fusion polypeptide consisting essentially of the polypeptide of (i) or (ii) connected to one or more other polypeptides.

18. (New) The method of claim 6, wherein the polypeptide having Calcineurin-binding activity is selected from the group consisting of:

(i) a polypeptide consisting essentially of the amino acid sequence set forth in SEQ ID No. 2 or 4; and

(ii) a fusion polypeptide consisting essentially of the polypeptide of (i) connected to one or more other polypeptides.